ATI RN
ATI Pathophysiology Exam 3
1. Which of the following is NOT an example of clinical manifestations of leukemia and lymphoma?
- A. Fatigue
- B. Increased risk of bleeding
- C. Increased risk of infections
- D. Increased energy and strength
Correct answer: D
Rationale: The correct answer is D: Increased energy and strength. Leukemia and lymphoma typically present with symptoms such as fatigue, weakness, increased risk of bleeding, and increased risk of infections. Patients with these conditions often experience a lack of energy and strength due to the disease's impact on the body. Therefore, increased energy and strength are not typical manifestations of leukemia and lymphoma.
2. A male patient is receiving testosterone therapy for hypogonadism. What adverse effect should the nurse monitor for during this therapy?
- A. Increased risk of cardiovascular events
- B. Increased risk of liver dysfunction
- C. Increased risk of prostate cancer
- D. Increased risk of bone fractures
Correct answer: A
Rationale: The correct answer is A: Increased risk of cardiovascular events. Testosterone therapy for hypogonadism is associated with an increased risk of cardiovascular events, such as myocardial infarction and stroke. Monitoring for signs and symptoms of cardiovascular issues is crucial during testosterone therapy. Choices B, C, and D are incorrect because testosterone therapy is not typically associated with an increased risk of liver dysfunction, prostate cancer, or bone fractures.
3. During surgery, the anesthesia personnel notice the client is having a steady rise in end-tidal carbon dioxide level. At this time, the nurse anesthetist begins to assess the client for malignant hyperthermia. The initial (priority) assessment for this disorder may include:
- A. measuring serum potassium levels.
- B. monitoring for muscle rigidity.
- C. evaluating renal function.
- D. checking arterial blood gases.
Correct answer: B
Rationale: The correct answer is B: monitoring for muscle rigidity. Muscle rigidity is a hallmark sign of malignant hyperthermia, a life-threatening condition triggered by certain anesthetics. Monitoring for this sign is critical in the early identification of the condition. Choices A, C, and D are not the initial priority assessments for malignant hyperthermia. Measuring serum potassium levels, evaluating renal function, and checking arterial blood gases are not specific initial assessments for malignant hyperthermia and would not aid in its early identification.
4. Medroxyprogesterone acetate (Provera) is indicated for the treatment of women with
- A. uterine bleeding.
- B. cervical cancer.
- C. ovarian cancer.
- D. fibromyalgia.
Correct answer: A
Rationale: Medroxyprogesterone acetate (Provera) is commonly used to treat conditions like abnormal uterine bleeding, amenorrhea, and endometriosis. It helps regulate the menstrual cycle and reduce excessive bleeding. Therefore, the correct answer is A. Choice B, cervical cancer, is incorrect because Provera is not indicated for the treatment of cancer. Choice C, ovarian cancer, is also incorrect as Provera is not a primary treatment for ovarian cancer. Choice D, fibromyalgia, is unrelated to the use of medroxyprogesterone acetate.
5. What aspect of this woman's current health status would contraindicate the use of oral contraceptives?
- A. The woman has a diagnosis of type 2 diabetes.
- B. The woman has asthma and uses inhaled corticosteroids and bronchodilators.
- C. The woman has a family history of breast cancer.
- D. The woman takes an antiplatelet medication for coronary artery disease.
Correct answer: A
Rationale: The correct answer is A. Women with type 2 diabetes are at higher risk of developing cardiovascular complications. Oral contraceptives further increase this risk due to their potential effects on blood pressure, lipid metabolism, and clotting factors. Choice B is incorrect as inhaled corticosteroids and bronchodilators do not contraindicate the use of oral contraceptives. Choice C is incorrect as a family history of breast cancer does not directly contraindicate the use of oral contraceptives. Choice D is also incorrect as taking an antiplatelet medication for coronary artery disease does not necessarily contraindicate the use of oral contraceptives.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access